Menarini Group, a privately held Italian pharmaceutical and diagnostics company, completed its acquisition of Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, for $677m. “The addition of ELZONRIS, which has potential to treat many other malignancies, as well as the other attractive pipeline assets augments our research and development capabilities and will accelerate our efforts to deliver novel oncology therapeutics to patients in need,” Elcin Barker Ergun, Menarini CEO.